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Abstract Introduction Criticisms have been raised against the sole use of p-value in interpret-
ing results from randomized controlled trials (RCTs). Additional tools have been
suggested, like the fragility index (FI), a measure of a trial’s robustness/fragility, and
derivative measures. The FI is the minimum number of patients who would have to be
converted from nonevents to events, in the group with the least events, for a result to
lose statistical significance.
Objective This study aimed to evaluate RCT supporting European Society of Cardiol-
ogy (ESC) guidelines regarding antithrombotics, using the FI and FI-related measures.
Methods FI, fragility quotient (FQ), and FI minus LTF lost to follow-up (FI LTF) were
calculated for the RCT underpinning recommendations regarding antithrombotic therapy
from the updated ESC guidelines. LTFwas comparedwith FI. Results were calculated for the
total group of studies, as per guideline and as per recommendation type.
Results Overall, 61 studies were included. The median FI was 24.5 (interquartile
range [IQR]: 9.0–60.0) and median FQ was 0.0035 (IQR: 0.0019–0.0056). Median
FI LTF was 2.0 (IQR: 0.0–38.0). Twenty (32.8%) of the studies had one primary ormain
safety outcome with LTF exceeding FI. Peripheral arterial disease guideline and chronic
coronary syndrome guideline had the lowest (2.5; IQR: 1.8–3.3) and the highest (48.5;
IQR: 23.8–73.0) FI, respectively.
Conclusion Themedian FI suggests robustnessofclinical trials evaluatingantithrombotic
drugs cited in the guidelines, but about one-third of them had LTF larger than FI. This
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Antithrombotic therapy, comprisinganticoagulant, antiplatelet,
and fibrinolytic drugs, is the current key treatment for some of
the major cardiovascular diseases. Decisions regarding the
treatment of these conditions are routinelymade in accordance
to guidelines, which are built based on randomized controlled
trials (RCTs), when available. Most often (though not always),
these RCTs display statistically significant results, a concept
based on p-value (the chance of obtaining results at least as
extremeprovided thenull hypothesis is true) of<0.05. For long,
thep-valuehas received criticism suchas thearbitrariness of its
cut-off for significance, the fact that it depends on the selected
statistical test and, not less importantly, that its truemeaning is
often misunderstood due to its complexity.1,2 Consequently,
movements have arisen claiming that other measures, with
different information, rather than or alongside the theoretical
p-value threshold of 0.05, should be reported.3
Thefragility index(FI) isoneof thosemeasures. Introduced in
1990byFeinstein4andbroughtback in2014byWalshet al,5 it is
a tool for assessing a trial’s robustness. It can be defined as the
minimum number of patients whowould have to be converted
fromnonevents to events, in the groupwith the least events, for
the results to losetheir statistical significance.Thelower it is, the
less robust or more fragile a study is considered.5–7 The FI gave
risetoother tools.Thefragilityquotient (FQ) is theratiobetween
FI and sample size, allowing the evaluation of a study’s fragility
in relation to its number of participants. A higher FQ represents
more robust outcomes.6 It is useful to compare robustness
between clinical trials of different dimensions, where the sole
use of the FI may causemisinterpretations. For example, if both
study A and study B have an FI of 10, it might be tempting to
think both studies are equally robust. However, if study A has a
sample size of 100 and study B of 1,000, FQ for study A is 0.1
whereas FQ for study B is 0.01.
Neither FI nor FQ has strict cut-offs under which they
must be analyzed. Instead, they are tools that must be
interpreted at light of each study’s characteristics. Hence,
FI is often compared with the number of patients lost to
follow-up (LTF). Having an LTF which exceeds the FI in a
certain RCT might be a warning sign for fragility. Therefore,
the difference between FI and LTF (FI LTF) can also be used
as a measurement for assessing fragility.8 The highest this
value is, the more robust is the study.
The matter of how robust a study is should be particularly
important when it supports guideline recommendations. In
this investigation, we propose to assess the robustness of the
outcomes of RCTunderpinning the recommendations regard-
ing antithrombotic therapy in the most recent versions of the
European Society of Cardiology (ESC) guidelines9 through the
FI and relatedmeasurements. The ESC guidelines were chosen
because of their importance for practicing physicians.
Materials and Methods
Identification of Studies
We performed a comprehensive search through the ESC
web site section “Guidelines & Scientific Documents” in
September 2019. The search was updated in Decem-
ber 2020 according to newly published guidelines. All
the latest versions of the guidelines were screened and
those mentioning antithrombotic therapy (either anti-
platelet, anticoagulant, or fibrinolytic) were selected. We
surveyed each of the selected guidelines, to identify every
recommendation level of evidence (LOE) A or B (the ones
which may be supported by RCT) regarding antithrombotic
therapy. Their citations were looked up on PubMed. We
performed a primary analysis of titles and abstracts. All
RCTs that seemed to fit the inclusion criteria were submit-
ted to a secondary full-text analysis. Inclusion criteria were
(1) RCT which assessed antithrombotic therapy in at least
one arm; (2) 1:1 random allocation ratio; (3) two parallel
arms, two-by-two factorial design or more than two
parallel arms, if the recommendation focused only on
two of them; (4) at least one dichotomous primary out-
come or main safety outcome as statistically significant
(p<0.05 or a 95% confidence interval [CI] that excluded
zero, as stated in each trial) for a null hypothesis that no
difference existed. Since publicly available data were
employed, institutional review board approval was not
applicable.
Data Extraction
First, we retrieved all recommendations on antithrombotic
therapy from the ESC guidelines, its LOE and class of recom-
mendation. Then, from each corresponding RCT, data was
extractedonto aprepiloted form (Microsoft Excel spreadsheet).
Data collection focused on primary andmain safety outcomes.
It included study identification, control, intervention, popula-
tion, sample size, control and experimental group sizes, out-
come description, number of events in the control and
experimental groups, p-value, CI, and total LTF.
Study Outcomes
The primary outcome of this investigation was the
fragility/robustness of RCT underpinning the recommenda-
tions from ESC guidelines regarding antithrombotic therapy,
assessed through the FI, FQ, and FI LTF.
Calculating FI, FQ, and FI LTF
The FIwas calculated for each outcome using an online calcula-
tor (available at: https://clincalc.com/Stats/FragilityIndex.aspx)
which follows the method described by Walsh et al; adding an
event from the group with the smallest number of events and
subtracting a nonevent from the same group, so as to keep the
total number of participants constant. Then, a two-sided Fish-
er’s exact test is recalculated. The process is automatically
repeatedby the calculator until the p-value is 0.05 orhigher.5,10
FQwas calculated by dividing each FI for the respective sample
size.6,7 FI LTFwas calculated by performing a regular subtrac-
tionbut, if the resultwasnegative (i.e., if theLTFoutweighed the
FI), it was considered as zero.8
Statistical Analysis
FI, FQ, and LTF median and interquartile ranges (IQRs) were
calculated for the whole group of included studies, as per
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guideline, as per class of recommendation, and as per LOE. To
avoid overvaluing studies repeatedly cited in guidelines, we
excluded the repetitions under the same guideline topic for
the purposes of global analysis and analysis per guideline.
LTF was compared with the FI for each outcome. We also
calculated FI LTF for the complete group of studies, as well
as its median and IQR. Categorical values were stated as
counts and percentages. Spearman’s correlation (R) was used
to assess the relationship between FI and sample size, FI and
recalculated p-value, FI and event rate, and FI LTF and
recalculated p-value. p-Values for the correlations were
calculated through a two-tailed Student’s t-test. All statisti-
cal analysis was done through the Microsoft Excel spread-
sheet, apart from calculation of p-values. These were
calculated through the ClinCalc online calculator, employing
Fisher’s exact test.10
Results
Selection of Trials and Data Analysis
A total of 18 ESC guidelines11–28 were initially identified as
mentioning in any way antithrombotic drugs, with 244
corresponding recommendations. This translated into a
sum of 269 studies. One hundred and fifty-five were paral-
lel-arm RCT of which 83 had two arms (or were two-by-two
factorial trials or trials with more than two arms of which
just two concerned the recommendation under which they
were cited) and at least one statistically significant primary
or main safety outcome. After excluding 22 trials which
presented only noninferiority analyses, we were left with a
final sample of 61 studies, with 109 corresponding recom-
mendations from 12 guidelines.11–20,26,27 Reasons for exclu-
sion can be found in ►Fig. 1.
Fig. 1 Flow diagram of included and excluded studies. ESC, European Society of Cardiology; RCT, randomized controlled trials.
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The median sample size of the studies included was 2,524
(IQR: 855–10,253). The details from the studies and end-
points are presented in ►Table 1.
There was a total of 109 recommendations in our analysis
(►Table 2). Most studies analyzed were used to support
recommendations class I and LOE A.
FI, LTF, and FI LTF
The median FI for all 61 trials was 24.5 (IQR: 9.0–60.0).
Characteristics of each included study, as well as respective
FI, FQ, and FI LTF can be found in the ►Supplementary
Tables S1 and S2. The median FI and IQR as per guideline is
presented in ►Fig. 2A. The guideline on peripheral arterial
disease15 had the lowest FI (2.5; IQR: 1.8–3.3). The chronic
coronary syndrome guideline20 had the highest FI (48.5; IQR:
23.8–73.0; ►Table 3).
Results for FI median and IQR as per class of recommen-
dation and LOE can be found in ►Fig. 2B. Recommendations
class III had the lowest FI (7.0; IQR: 4.0–8.0).
Sixteen (26.2%) of the 61 trials did not disclose number of
LTFs. For the totality of studies which did, median LTF was
14.0 (IQR: 7.0–139.0). Median LTF was 13.0 (IQR: 7.0–16.3)
for class I; 37.0 (IQR: 6.0–255.0) for class IIa; 139.0 (IQR:
10.0–255.0) for class IIb; and 5.5 (IQR: 3.0–19.3) for class III.
LOE A had a median LTF of 14.0 (IQR: 9.0–255.0); LOE B had
also a median of 14.0 (IQR: 6.0–44.0). Twenty (32.8%) studies
had one primary outcome or main safety outcome in which
the LTF exceeded the FI. Four (6.6%) of the 61 trials had a
primary outcome or main safety outcome with a FI of 0.
►Fig. 3 shows the frequencies for FI, LTF, and FI LTF.
Median FI LTF was 2.0 (IQR: 0.0–38.0). But 45.0% of the
results included had a FI LTF of 0.
Correlations were R¼ 0.77 between FI and p-value
(p<0.001), R¼0.42 between FI and sample size (p<0.001),
R¼0.26 between FI and event rate (p<0.001), and R¼ 0.34
between FI LTF and p-value (p<0.001; ►Fig. 4).
Fragility Quotient
Regarding the FQ, its median for the total of studies was
0.0035 (IQR: 0.0019–0.0056). For class I, it is 0.0041 (IQR:
0.0019–0.0058); 0.0035 (IQR: 0.0026–0.0094) for class IIa;
0.0026 (IQR: 0.0018–0.0036) for class IIb; and 0.0019 (IQR:
0.0017–0.0030) for class III. Recommendations LOE A had a
FQ median of 0.0039 (IQR: 0.0019–0.0059) and LOE B had
0.0028 (IQR: 0.0018–0.0041). The guideline on valvular heart
disease had the highest FQ and the one on myocardial
infarction with ST elevation had the lowest FQ.
Discussion
Our researchestablished the fragilityof trial outcomes from61
RCTs supporting recommendations regarding antithrombotic
therapy from the updated versions of ESC guidelines. Our
median FIwas 24.5 (IQR: 9.0–60.0)which is higher thanvalues
reported in previous studies in the cardiovascular field.29,30
The peripheral artery disease guideline15 had the lowest FI
(2.5; IQR:1.8–3.3)which suggests theRCTsunderpinning it are
more fragile. For the analysis of thisguideline, only two studies
were included, due to restrictions inherent to the FI method.
One of the studies included was CAPRIE (clopidogrel versus
aspirin in patients at risk of ischaemic events),31 a trial well
known for the fragility of its results, with a borderline statisti-
cally significant p-value of 0.043 for its main outcome. The
other study included byDonaldson et al32 had a sample size of
65 for its main outcome (and a p-value calculated by us of
0.003). Hence, we can here see in practice that both borderline
p-values and a small sample size contribute to a low FI.
The chronic coronary syndrome guideline,20 on the other
hand, had the highest FI (48.5; IQR: 23.8–73.0). Likely, the
high sample sizes of the studies included for this guideline
were the determining factor for this high fragility index. Of
the six studies, five had more than 1,000 participants and
Table 1 Characteristics of randomized controlled trials cited in
the guidelines
Characteristics n (%)/median (IQR)
Number of trials 61







Number of patients LTF 13.0 (3.5–39.5)
Recalculated p-valuea 62b (100)




Abbreviations: IQR, interquartile range; LTF, lost to follow-up.
Note: Numbers reported as total (%) or median (IQR).
ap-Values calculated using Fisher’s exact test.
bOne study with factorial two-by-two design was counted twice, since
the two pairs of arms were analyzed as individual studies.
Table 2 Number of randomized controlled trials supporting




Class I 52 34
Class IIA 27 19
Class IIB 24 18
Class III 6 6
LOE A 63 49
LOE B 46 28
LOE C 0b 0
Abbreviations: LOE, level of evidence; RCT, randomized controlled trials.
aNumber of studies supporting each class/LOE. Studies were counted
more than once when they supported recommendations with different
class/LOE.
bSince we only included RCT, there are no recommendations LOE C.
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two of these had over 15,000. The smallest sample size in this
group was of 563.
The median FI LTF in our analysis was 2.0 (IQR: 0.0–-
38.0), meaning that in half of the studies, the number of LTF
patients is superior, equal, or very close to the number of
patients whose outcome would have to change to render
these trials’ results nonstatistically significant. The interpre-
tation of these findings, as well as the portion result with an
FI LTF value of 0, is limited by the fact that our analysis
included several repetitions, as well as by the fact that it uses
total rather than intervention or LTF control. Nonetheless, it
may help interpret the overall robustness, if we consider the
number of times, a study is cited in the guidelines is directly
proportional to its relative importance in their building.
Additionally, in our investigation, 20 of the 61 trials
(32.8%) had a primary or main safety outcome in which
the LTF outweighed the FI. Conclusions derived from out-
comes where the LTF matches or exceeds the FI should be
taken with caution. It may have been that those patients
vanished from some unfortunate twist of faith (thefigurative
slip on a banana peel), or that they actually experienced the
study’s outcome, or both. The comparison of FI and LTF is,
therefore, much more valuable than classifying an FI as high
or low, a point of difference from the p-value. Nevertheless,
we must keep in mind, it is unlikely that all patients lost
during follow-up would have turned out to be events from
the study arm with the lowest event rate. Most likely, they
were distributed between the two groups and some of them
would end up suffering the study outcome while others
would not, had they remained throughout the whole length
of the trial. But since we cannot guarantee that this was the
case, we have to admit the possibility of the results being
changed by the LTF patients, especially in those studies
where the LTF largely outweighs the FI.
Another point of interest is outcomes with an FI of 0. We
reported a total of four (6.6%) studies with a primary or main
safety outcome with an FI of 0, meaning that, without
changing the number of events, nonstatistically significant
results would have been obtained had the choice of another
statistical test. Correspondingly, on ►Table 1, we reported
four studies with a p-value of 0.05, determined through
Fisher’s exact test before calculating the FI. The smallest
number of participants reported in this group of RCT was
840. Of the other three studies, one had a sample size of 900
and two had sample sizes over 1,000. Considering none of
these numbers is small enough to render Fisher’s exact test,
the only statistical test suitable, the authors’ choice of using
other tests in the statistical analysis can be reasonable.
Our analysis also sought to determine the FQ for each
outcome. The median FQ was 0.0035 (IQR: 0.0019–0.0056),
denoting that there would be no statistical significance if
0.35 in 100 patients had experienced a different event. The
guideline on valvular heart disease had the highest FQ
(0.0835; IQR: 0.0835–0.0835). For the analysis of this guide-
line, only one study fit the inclusion criteria. This study, by
Dewilde et al,33 scored an FI of 47, giving this guideline
Fig. 2 Fragility Index per Guideline and per Type of Recommendation. (A) Fragility index per guideline. (B) Fragility index per type of
recommendation. Results presented as median and interquartile range. AF, atrial fibrillation; CCS, chronic coronary syndrome; CV Prev,
cardiovascular prevention; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; FI, fragility index; HCM, hypertrophic cardiomyopathy; LOE,
level of evidence; MR, myocardial revascularization; n, number of studies supporting each guideline; NSTEMI, non-ST elevation myocardial
infarction; Nt, number of studies supporting all guidelines; PAD, peripheral arterial disease; PE, pulmonary embolism; STEMI, ST elevation
myocardial infarction; VHD, valvular heart disease. Nt differs from the sum of all N because some studies appear in more than one guideline.
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the second highest FI. This, along with a relatively small
sample size comparing to other included studies (563
patients allocated) is likely why this guideline had the high-
est FQ. Both the FI and FQ displayed a decreasing tendency
from recommendations from class I to those class III which
suggests recommendations in favor of a certain practice are
generally supported bymore robust trials than those against
it. In the case of recommendations, class III, mean evidence
Table 3 FI, FQ, and LTF dispersion as per guideline, class of recommendation, and LOE
Guideline FI Q1 FI Q2 FI Q3 FQ Q1 FQ Q2 FQ Q3 LTF Q1 LTF Q2 LTF Q3
AF (n¼11) 8.5 17.0 50.0 0.0041 0.0082 0.0146 3.0 6.5 7.8
CCS (n¼ 6) 23.8 48.5 73.0 0.0033 0.0049 0.0287 6.8 27.5 44.0
CV prev (n¼4) 24.0 35.0 64.0 0.0019 0.0035 0.0048 13.0 14.0 255.0
DAPT (n¼ 13) 17.0 26.0 64.0 0.0019 0.0035 0.0049 13.0 14.0 255.0
DM (n¼7) 12.3 18.0 28.3 0.0013 0.0022 0.0030 14.0 91.5 255.0
HCM (n¼1) 17.0 17.0 17.0 0.0023 0.0023 0.0023 43.0 43.0 43.0
MR (n¼ 20) 4.5 20.0 60.0 0.0019 0.0039 0.0051 10.0 14.0 80.3
NSTEMI (n¼21) 13.0 34.0 62.5 0.0019 0.0035 0.0050 11.5 16.0 44.0
PAD (n¼ 2) 1.8 2.5 3.3 0.0154 0.0308 0.0462 10.5 21.0 31.5
PE (n¼ 7) 2.0 3.0 8.0 0.0030 0.0033 0.0119 5.0 7.0 14.0
STEMI (n¼ 12) 12.0 24.0 68.0 0.0012 0.0019 0.0044 7.0 14.0 42.0
VHD (n¼ 1) 47.0 47.0 47.0 0.0835 0.0835 0.0835 2.0 2.0 2.0
Class I (n¼34) 4.0 35.0 68.0 0.0019 0.0041 0.0058 7.0 13.0 16.3
Class IIa (n¼19) 14.8 26.0 47.0 0.0026 0.0035 0.0094 6.0 37.0 255.0
Class IIb (n¼18) 14.8 23.5 34.0 0.0018 0.0026 0.0036 10.0 139.0 255.0
Class III (n¼ 6) 4.0 7.0 8.0 0.0017 0.0019 0.0030 3.0 5.5 19.3
LOE A (n¼ 49) 10.0 26.0 64.0 0.0019 0.0039 0.0059 9.0 14.0 255.0
LOE B (n¼ 28) 4.0 14.0 34.0 0.0018 0.0028 0.0041 6.0 14.0 44.0
Total (Nt¼61)a 9.0 24.5 60.0 0.0019 0.0035 0.0056 7.0 14.0 139.0
Abbreviations: AF, atrial fibrillation; CCS, chronic coronary syndrome; Class, class of recommendation; CV prev, cardiovascular prevention; DAPT,
dual antiplatelet therapy; DM, diabetes mellitus; FI, fragility index; FQ, fragility quotient; HCM, hypertrophic cardiomyopathy; LOE, level of evidence;
LTF, lost to follow-up; MR, myocardial revascularization; n, number of studies supporting each guideline/class/LOE; NSTEMI, non-ST elevation
myocardial infarction; Nt, number of studies supporting all guidelines; PAD, peripheral arterial disease; PE, pulmonary embolism; Q1/Q2/Q3,
quartile 1/2/3; STEMI, ST elevation myocardial infarction; VHD, valvular heart disease.
aNt differs from the sum of all n because some studies appear in more than one guideline.
Fig. 3 Frequencies of different outcomes. (A) Frequencies of fragility indices, (B) patients lost to follow-up and (C) fragility index minus lost to
follow-up. The X-axis represents the FI (A), the LTF (B) and the FI LTF (C). The Y-axis represents the number of times each value was entered to
our global analysis (as described in the section Materials and Methods—Statistical Analysis). FI, fragility index; FI LTF, FI minus lost to follow-up.
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for harm (since we only included statistically significant
results) in these trials is fragile and there may be instead
just a lack of benefit in the intervention.
Similarly to previous findings by Gaudino et al,30 therewas
a considerable negative correlation between FI and p-value
(R¼ 0.77,p<0.001).Also, theFI showedamoderatepositive
correlation to sample size (R¼0.42, p<0.001) which is in
agreement with the values reported by Khan et al (R¼0.32)29
and Gaudino et al (R¼0.35).30 The increase in the size of
samples seems then to be a candidate for fixing the fragility
problemwhendesigninga trial. Although it is true that authors
walk a fine line when trying to balance attempts to make a
study as robust as possible, while respecting ethical principles
which state that a hypothesis should be tested on as few
patients as possible, it is also true that fragile studies with
unreliable results which do not provide good quality evidence
are, themselves, ethically censurable. Furthermore, they call
for additional studies on the same topic, requiring, in the end,
moreparticipants than itwouldhave, a singlemore robust trial
been performed from the beginning.
Limitations
Our study has some limitations, the main one being not
including systematic reviews with meta-analysis which are
a great part of the evidence behind recommendations. Addi-
tionally, due to the constraints imposedby theFImethod itself,
only 61 RCTs were eligible for analysis. Finally, since trials are
powered for primary outcomes, we decided to leave
out secondary ones. It is also important to emphasize that
we selected only trials referred in the guidelines, whichmeans
we might be at risk of study selection bias. Even though it is
known that guideline recommendations are increasing, LOE A
(higher level) and class-I or -III recommendations are decreas-
ing. Therefore, it is important tohave tools to criticallyappraise
the evidence in the setting of guidelines.9
Fig. 4 Correlation between fragility index and trial characteristics. (A) Correlation between fragility index and p-value (R¼  0.77), (B) fragility
index and sample size (R¼ 0.42), (C) fragility index and event rate (R¼ 0.26), and (D) fragility index minus lost to follow-up and p-value
(R¼  0.34). FI, fragility index; FI LTF, FI minus lost to follow-up.
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Besides the restrictions which partially shaped our study,
others are worthy of note: the FI may not be suitable for time-
to-event outcomes, particularly when the number of events in
the control and experimental groups is similar, but there is a
marked difference in their timings.5 This is mostly important
for trials in the area of oncology; additionally, since it is not a
measure of effect (much like the p-value) it cannot be used on
its own to interpret the result of a trial.34 Finally, some
investigations35 have shown strong correlation between the
FI and p-value, leading some authors to state this may be a
superfluous tool.34
Conclusion
The FI has not come to replace statistical significance. In fact,
it is an absolute measure, like others which exist (as the
number needed to treat/harm) that aids physicians in better
understanding the robustness of trials beyond relative risks
and p-values. The results of our analysis show that most of
the statistically significant studies cited in guidelines to
address clinical recommendations have a good fragility
index. This means that more than a few additional events
are required to cause loss of statistical significance. In our
view, the FI, as the most intuitive and thus far studied
fragility tool here presented, should be taken into account,
when applicable, in the creation of future recommendations
for clinical practice guidelines, alongside the p-value and CI.
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